about
Effectiveness of statin therapy in adults with coronary heart disease.Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial.Rates and correlates of potentially inappropriate colorectal cancer screening in the Veterans Health Administration.Unintended consequences of implementing a national performance measurement system into local practice.Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials.Relation of heart rate parameters during exercise test to sudden death and all-cause mortality in asymptomatic men.Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials.Dose dependent effect of statins on postoperative atrial fibrillation after cardiac surgery among patients treated with beta blockers.ACP Journal Club. Review: statins reduce pancreatitis in adults with normal or mildly elevated triglyceride levels.A conceptual framework for understanding and reducing overuse by primary care providers.Screening pelvic examinations in asymptomatic, average-risk adult women: an evidence report for a clinical practice guideline from the American College of Physicians.ACP Journal Club: adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events.Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial.Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial.The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial.Are gender differences in colorectal cancer screening rates due to differences in self-reporting?Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial.Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial.More than a score: a qualitative study of ancillary benefits of performance measurement.Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes.Long term clinical trials: how much information do participants retain from the informed consent process?Prognostic Significance of Elevated Cardiac Troponin I After Heart SurgeryThe trouble with triglyceridesHigh-density lipoprotein and coronary heart disease: lessons from recent intervention trialsThe role of fibrates in a statin worldSelf-monitoring of oral anticoagulation reduces thromboembolic events and does not increase risk of bleeding in selected patients and settingsACP Journal Club. High-dose oral multivitamins and minerals after MI did not reduce CV eventsScreening pelvic examinations in asymptomatic, average-risk adult women
P50
Q33204656-F20EBC41-DF94-40E7-8DFD-BC52DAF531C0Q34092876-FD66A9AA-1742-4443-B263-EF2C02D2796CQ35638126-1900536D-63E5-4072-8C5E-E9090958A41DQ35831119-6EF7ED93-3AB2-4469-8943-68ADB5F8C628Q36372677-D7AD6B63-0AE4-4434-A620-8A3CDA43AA4EQ36532738-21241E7A-3801-4A75-ACBA-BD6DDC42C085Q36737746-9D12B07F-069D-4E6A-992C-43A952F66ECAQ37285952-F7386524-BEC9-4D32-A776-807B76D39639Q37422347-B1B268AA-FB49-4C98-B8D9-A7C4553C59F1Q38068137-9702A152-A4F4-404B-B7B0-1E1E1413E0E9Q38126736-FE8E81B1-6078-45E5-86D8-1E3A8B8DA454Q38224723-F6555592-0DD6-40B2-84F9-B766B80358B6Q41658643-465F44AD-BCBF-48D5-9B3E-625F4633D790Q44063968-C6141C77-F75F-41C5-92CE-BF5D3149133DQ45006115-95197163-3609-41EF-86E7-F3B77810D84FQ45028934-0C4A2DAC-44BE-4980-8407-2E7EED2907B8Q45113794-63759AAD-9429-4728-91ED-BC40A12D42F4Q45331985-E7EC7486-D52E-4A55-99BB-7BF46AF82CC9Q45332435-0D9A0227-EF49-4849-8A15-2F70B3C5AECBQ45332631-FCEF054D-6E8B-4B96-A359-CC48EF706BF6Q45332939-449986B1-977F-4508-A266-5B962197FA59Q45332981-46B79D59-A2FE-4BD3-A5A8-0338F3FF47AFQ45333030-54A7DE27-98AA-4212-9E89-F06A2609270BQ45925671-CDECC073-2B76-45A6-B554-DCC3A8BB003EQ46045979-02234960-8DB9-4EC3-8A37-5AC7FF5CDDD4Q46731311-5231CB21-479B-4765-86ED-F024C7C4438DQ47800022-32E4959A-56B4-4A00-91A3-8BAE815168B6Q48144070-558365A5-3563-48F6-965A-AB066FB7A8EFQ51981504-95EDE451-C8E5-4FD6-A895-6552300F81F8Q58804616-D102E188-3D91-41AC-9072-EA4DE45C6597Q73977328-4DF9A22B-8220-4561-922B-9A04889C8064Q77613812-2BFF7CEE-4BBC-4917-9A5A-FC91FEA08880Q83136850-C80AAEB7-1FBC-4AC5-BE05-65436FD1B92EQ83916319-85096239-74A7-402B-9525-BBFC07A99FB1Q87908634-858ED53B-9FF6-45E4-A072-108A478F9A15Q95616016-783F34A9-9ADD-4A89-AED8-EC6A0B476AE7
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hanna E Bloomfield
@ast
Hanna E Bloomfield
@en
Hanna E Bloomfield
@es
Hanna E Bloomfield
@nl
type
label
Hanna E Bloomfield
@ast
Hanna E Bloomfield
@en
Hanna E Bloomfield
@es
Hanna E Bloomfield
@nl
prefLabel
Hanna E Bloomfield
@ast
Hanna E Bloomfield
@en
Hanna E Bloomfield
@es
Hanna E Bloomfield
@nl
P108
P106
P1153
35516047300
8903491600
P31
P496
0000-0002-0756-7064